ArticleJournal of applied toxicology : JAT2026
Acute Toxicity and Genotoxicity of cMoL, a Lectin From Moringa oleifera Seeds With Antifungal Activity Against Cryptococcus Strains.
Article in Journal of applied toxicology : JAT, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Acute Toxicity and Genotoxicity of cMoL, a Lectin From Moringa oleifera Seeds With Antifungal Activity Against Cryptococcus Strains.Journal of applied toxicology : JAT · 2026Article
- Targeting Yeast Pathogens with Lectins: A Narrative Review from Mechanistic Insights to the Need for Addressing Translational Challenges.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Coagulant Moringa oleifera lectin (cMoL) is one of the compounds involved in the application of M. oleifera seeds for traditional water treatment methods. The present study highlights the new biotechnological potential of cMoL lectin as an antifungal agent against Cryptococcus neoformans B3501 and H99 and Cryptococcus gattii R265 strains. Acute toxicity and genotoxicity were assessed to provide information on security utilization. The antifungal activity was evaluated using the broth microdilution test, flow cytometry, antibiofilm activity, and synergistic effects with fluconazole. Acute toxicity was determined by administering a single dose of cMoL (200 mg/kg) to female Swiss albino mice and examining the following parameters: water and feed consumption, weight variation, blood hematological and biochemical parameters, serum cytokine levels, and histopathological analyses. Genotoxicity was assessed using comet assay and micronucleus test. cMoL inhibited the growth of all tested isolates, with a minimal inhibitory concentration of 7.5 μg/mL. Flow cytometry data showed that cMoL (7.5 μg/mL) significantly decreased cell viability by promoting necrosis. cMoL was not found to be an antibiofilm agent against Cryptococcus species; however, it acted synergistically with fluconazole against C. neoformans H99. cMoL (200 mg/kg) did not cause animal death or toxicity. No hematological, biochemical, histopathological, or genotoxic effects were observed. These results encourage the exploration of cMoL as a natural and safe antifungal agent against Cryptococcus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.